Capricor Therapeutics receives a STRONG SELL rating due to high regulatory risk surrounding its DMD therapy, Deramiocel. Hope-3 trial data reporting is confusing, with p-values for the primary ...
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...
Based on prior, preclinical and clinical data, including 2 small randomized trials, I believe there is a high probability that Capricor Therapeutics' phase 3 trial will be positive. Topline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results